Canaccord Genuity Group Increases LifeStance Health Group (NASDAQ:LFST) Price Target to $10.00

LifeStance Health Group (NASDAQ:LFST) had its price objective lifted by Canaccord Genuity Group from $9.00 to $10.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective points to a potential upside of 43.97% from the stock’s previous close.

Other research analysts have also issued reports about the company. BTIG Research increased their price objective on LifeStance Health Group from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday, February 2nd. KeyCorp increased their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday. Wall Street Zen upgraded shares of LifeStance Health Group from a “hold” rating to a “buy” rating in a research note on Sunday, February 8th. UBS Group upped their price objective on shares of LifeStance Health Group from $10.00 to $12.00 and gave the company a “buy” rating in a report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $9.67.

LifeStance Health Group Stock Performance

LFST stock traded down $0.46 during trading on Thursday, reaching $6.95. The company had a trading volume of 8,131,978 shares, compared to its average volume of 1,962,015. The company has a market cap of $2.70 billion, a price-to-earnings ratio of -231.53 and a beta of 1.12. LifeStance Health Group has a twelve month low of $3.74 and a twelve month high of $8.30. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.58 and a current ratio of 1.58. The firm has a 50-day simple moving average of $7.12 and a 200-day simple moving average of $6.18.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.02). LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.The company had revenue of $382.20 million during the quarter, compared to analysts’ expectations of $378.51 million. During the same period in the prior year, the business posted ($0.01) EPS. The company’s quarterly revenue was up 17.4% on a year-over-year basis. As a group, sell-side analysts expect that LifeStance Health Group will post -0.18 earnings per share for the current year.

LifeStance Health Group declared that its board has initiated a stock repurchase plan on Wednesday, February 25th that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the company to repurchase up to 3.6% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, insider Ann Varanakis sold 50,000 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total value of $345,000.00. Following the completion of the transaction, the insider owned 315,610 shares in the company, valued at approximately $2,177,709. This represents a 13.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Robert Bessler sold 119,942 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $7.04, for a total value of $844,391.68. Following the sale, the director owned 1,318,983 shares in the company, valued at $9,285,640.32. This trade represents a 8.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 270,086 shares of company stock worth $1,891,264. 3.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. increased its holdings in LifeStance Health Group by 6.9% in the 4th quarter. Invesco Ltd. now owns 205,486 shares of the company’s stock worth $1,447,000 after acquiring an additional 13,177 shares in the last quarter. Vident Advisory LLC increased its stake in shares of LifeStance Health Group by 148.8% during the fourth quarter. Vident Advisory LLC now owns 37,462 shares of the company’s stock worth $264,000 after purchasing an additional 22,406 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of LifeStance Health Group during the 4th quarter worth about $96,000. Zacks Investment Management lifted its stake in LifeStance Health Group by 33.1% in the 4th quarter. Zacks Investment Management now owns 45,291 shares of the company’s stock valued at $319,000 after buying an additional 11,270 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in LifeStance Health Group by 58.8% in the 4th quarter. Janus Henderson Group PLC now owns 94,500 shares of the company’s stock worth $666,000 after buying an additional 35,000 shares during the last quarter. Hedge funds and other institutional investors own 85.50% of the company’s stock.

Key Headlines Impacting LifeStance Health Group

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q4 / FY2025 results and 2026 outlook show solid demand and margin progress: revenue +17% in Q4 to $382.2M, positive net income and a meaningful rise in Adjusted EBITDA; management guided 2026 revenue to $1.615B–$1.655B and raised EBITDA expectations, giving a clear growth + profitability story that supports longer‑term upside. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Board authorized a $100M share repurchase program (up to ~3.6% of shares), a capital-allocation move that signals management believes shares are undervalued and can support the stock over time. Press Release
• Positive Sentiment: Analyst support increased: UBS raised its price target to $12 with a Buy and KeyCorp lifted its target to $9 with an Overweight rating — both represent meaningful upside from current levels and can help sustain demand from institutional buyers. Analyst Price Target Raises
• Neutral Sentiment: Company reiterated 1Q26 revenue range ($380M–$400M) and provided detailed center‑margin / EBITDA targets — helpful for modeling but not a surprise given the Q4 print. Earnings Presentation
• Negative Sentiment: Selling stockholders launched a secondary offering of 25M shares (company receives no proceeds), which creates near‑term selling pressure and increases float — a likely key reason for downward pressure despite operational strength. Secondary Public Offering
• Negative Sentiment: EPS missed some sell‑side expectations (reported ~$0.03 vs. consensus ~$0.05), which—combined with the secondary offering and heavy insider/selling‑holder activity reported in filings—has likely amplified intraday weakness even though revenue beat and margins improved. Earnings Call Transcript

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.